

THE LANCET

Infectious Diseases

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Peeling RW, Olliaro PL, BoerasDI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. *Lancet Infect Dis* 2021; published online Feb 23. [https://doi.org/10.1016/S1473-3099\(21\)00048-7](https://doi.org/10.1016/S1473-3099(21)00048-7).

Appendix

Table 1. Performance of Selected WHO Emergency Use authorised Antigen Rapid Tests

Evaluation sites		Switzerland		Germany
Abbott Panbio Ag-RDT	N	NP swabs	N	NP swabs
Clinical Sensitivity	124	86%	106	87%
- ≤7 days after symptom onset	111	86%	76	91%
- High viral load (Ct value ≤25)	93	97%	72	96%
- Includes low viral load (Ct value ≤33)	116	90%	103	88%
Clinical Specificity	411	100%	1002	99.9%
SD Biosensor Ag-RDT	N	Switzerland	N	Brazil
Clinical Sensitivity	191	89%	106	87%
- ≤7 days after symptom onset	176	90%	97	91%
- High viral load (Ct value ≤25)	141	97%	49	96%
- Includes low viral load (Ct value ≤33)	183	92%	99	92%
Clinical Specificity	328	99.7%	294	98%